Clinical Trial Update: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating a combination of azacitidine, mitoxantrone hydrochloride, and etoposide in older patients with poor-prognosis acute myeloid leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Acute Myeloid Leukemia Without Maturation
• Acute Myeloid Leukemia with Cbfb-myh11
• Acute Myeloid Leukemia with Inv Cbfb-myh11
• Acute Myeloid Leukemia with Minimal Differentiation
• Acute Myeloid Leukemia with Mllt3-mll
• Acute Myeloid Leukemia with Runx1-runx1t1

Drugs mentioned

• Etoposide (Etoposide)
• Mitoxantrone hydrochloride (mitoxantrone)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 1 | Status: TERMINATED